Associate professor

US Air Force Awards Skyloom $18M to Develop Hybrid Space Optical Satellite Communications to Support Assured C3ISR

Retrieved on: 
Monday, April 8, 2024
Knowledge, Transfer, LEO, Element, Associate professor, Altitude, Skybridge, Government, Environment, Partnership, SBIR, STTR, Policy, Small business, SKY PerfecTV!, Commercial, Small Business Innovation Research, AFWERX, USAF, KBI, Air force, Allied forces, NTT, Air Force Research Laboratory, DAF

The contract will allow Skyloom to develop network infrastructure elements of Space Optical Satellite Communications for a Hybrid Space Architecture to augment assured communications in a contested environment.

Key Points: 
  • The contract will allow Skyloom to develop network infrastructure elements of Space Optical Satellite Communications for a Hybrid Space Architecture to augment assured communications in a contested environment.
  • Skyloom and SkyBridge, a subsidiary of Knowledge Bridge International, Inc. (KBI) will collaborate to bring the solutions to use.
  • Each of these elements are fundamental building blocks for the future of U.S. and Allied assured communications that are already evolving through free-space optical technology.
  • “STRATFI accelerates the production and operational readiness of Space Optical Satellite Communications for Government and Commercial End-Users.

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

Retrieved on: 
Sunday, April 7, 2024
Diamond, EGFR, Helmy Eltoukhy, Mutation, Prevalence, NSCLC, Survival, Foundation Medicine, Patient, Cancer, Lung cancer, AACR, PACC, TKI, Drug resistance, MD Anderson Cancer Center, Associate professor

CAMBRIDGE, Mass., April 07, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, presented real-world evidence of the evolving epidermal growth factor receptor (EGFR) mutation landscape in non-small cell lung cancer (NSCLC), and the potential of BDTX-1535 to address a broader range of mutations compared to existing therapies. The results were disclosed in an oral presentation on April 7, 2024, at the 2024 American Association of Cancer Research (AACR) Annual Meeting held in San Diego, California.

Key Points: 
  • The results were disclosed in an oral presentation on April 7, 2024, at the 2024 American Association of Cancer Research (AACR) Annual Meeting held in San Diego, California.
  • The analyses reveal a broad spectrum of non-classical mutations, as well as an increased prevalence of the acquired resistance mutation, C797S.
  • The compound also potently inhibits the drug resistance C797S mutation, which emerges following treatment with third-generation EGFR inhibitors, including osimertinib.
  • Black Diamond is currently advancing BDTX-1535 in a Phase 2 trial for patients with EGFRm NSCLC across multiple lines of therapy.

CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy

Retrieved on: 
Saturday, April 6, 2024
Guillain–Barré syndrome, Bone marrow, Medical College of Wisconsin, Encephalopathy, Survival, Immunotherapy, BCMA, Patient, Hypotension, Mortality, B-cell maturation antigen, Edema, Periodic breathing, Associate professor, Dexamethasone, Certification, Neutropenia, Dizziness, Risk, Headache, Chills, Myelodysplastic syndrome, Coagulopathy, DPD, Johnson & Johnson, Immune system, Effect, Fatigue, Thrombocytopenia, Food, Disease, Drive, Appetite, Lymphocytopenia, JNJ, Constipation, Multiple myeloma, Acute myeloid leukemia, CRS, Death, Hypersensitivity, Cytopenia, Cytokine release syndrome, ASCO, Use, Hematology, FDA, PVD, Annual general meeting, T cell, DSM-IV codes, Incidence, Tachycardia, Bortezomib, Diarrhea, Viral, Hope, United, Cough, Daratumumab, Nausea, Society, Division, Physician, Pharmaceutical industry

HORSHAM, Pa., April 5, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.1 With this approval, CARVYKTI® becomes the first and only B-cell maturation antigen (BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as first relapse.

Key Points: 
  • "This milestone underscores our commitment to improve outcomes for patients and transform the treatment of multiple myeloma with CARVYKTI," said Jordan Schecter, M.D., Vice President, Disease Area Leader, Multiple Myeloma, Johnson & Johnson Innovative Medicine.
  • CARVYKTI® is a cell therapy that works by harnessing a patient's immune system, or T cells, to fight the disease.
  • Treatment requires extensive training, preparation, and certification to ensure a positive experience for patients.
  • Since initial approval in February 2022, Johnson & Johnson has made significant advances in manufacturing to rapidly scale CARVYKTI® production.

Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic

Retrieved on: 
Monday, March 25, 2024
Diagnosis, Certification, LM, Plus Therapeutics, NSCLC, CSF, Partnership, Central nervous system, Patient, CNS, Breast, PSTV, Lung cancer, Clinical trial, Therapy, Cancer, Rhenium, CLIA, Research institute, Cancer prevention, Feinberg School of Medicine, Associate professor

AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) --  Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it has successfully completed key validation testing and implementation of its tumor cell enumeration assay, known as CSF-01, to be used initially as an exploratory endpoint in its ReSPECT-LM clinical trials.

Key Points: 
  • “In mid-2023, the Company licensed CSF-01, as well as a broader CSF diagnostic testing portfolio due to high conviction that routine implementation will substantially improve diagnosis and clinical management of LM,” said Marc H. Hedrick, M.D., President & CEO of Plus Therapeutics.
  • While validated for use in Plus’ clinical development programs, full Clinical Laboratory Improvement Amendments (CLIA) certification is not anticipated until 2025.
  • The ReSPECT-LM trial, including support for CSF-01 testing, is currently receiving grant funding from the Cancer Prevention and Research Institute of Texas (CPRIT).
  • If the FORSEE data is positive, we intend to work toward increasing commercial reimbursement for the CLIA-certified test and explore partnerships to maximize diagnostic utilization for the broader CNS cancer space.

MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Toxicity, Aplastic anemia, Salvage therapy, CLL, AML, CRi, Patient, Venetoclax, Biomarker, Diarrhea, BCL2, University, Acute myeloid leukemia, ELN, Safety, Pharmacokinetics, CDK9, Phase 1, Associate professor, Pharmaceutical industry

The study is currently enrolling a 12-patient expansion cohort evaluating voruciclib administered at 300 mg daily for two weeks in a four-week cycle in combination with venetoclax.

Key Points: 
  • The study is currently enrolling a 12-patient expansion cohort evaluating voruciclib administered at 300 mg daily for two weeks in a four-week cycle in combination with venetoclax.
  • A total of 29 patients with R/R AML, median age 67 years (range 34-89), enrolled in the dose escalation stage of the study evaluating voruciclib in combination with venetoclax.
  • The primary objectives of the study are to determine the safety and biologic effective dose of voruciclib monotherapy or voruciclib in combination with venetoclax.
  • Secondary objectives of the study include assessing the preliminary efficacy, pharmacokinetics, pharmacodynamics, and biomarkers of voruciclib monotherapy or voruciclib in combination with venetoclax.

Lumicell Introduces Further Research and Insights in Fluorescence-Guided Surgery at the Society of Surgical Oncology (SSO) Annual Meeting

Retrieved on: 
Monday, March 25, 2024
Health, Surgery, Oncology, Medical Devices, Breast cancer, Feasibility, Detection, DVS, Massachusetts General Hospital, Light, Inc., Patient, Neoplasm, Stanford University Medical Center, NDA, University, Doctor of Philosophy, Society, Surgeon, Patient satisfaction, Surgical oncology, SSO, Hospital, PMA, Multimedia, MD Anderson Cancer Center, FDA, Associate professor, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20240325761901/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240325761901/en/
    Barbara Smith, M.D, PhD., presented results from the INSITE study during the Breast Cancer Hub Zone talk during the SSO Annual Meeting 2024.
  • “It’s so energizing to see such a diversity of surgeons across different specialties come together to advance the collective field of surgical oncology,” said Jorge Ferrer, M.D., PhD, Chief Scientific Officer, Lumicell.
  • Most recently, the FDA’s Medical Imaging Drugs Advisory Committee (MIDAC) voted in support of the benefit-risk profile of LUMISIGHT™ (pegulicianine) during its March 5, 2024 meeting .
  • The FDA is expected to make a decision on Lumicell’s NDA and PMA in the near future.

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Retrieved on: 
Friday, March 15, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, SLL, BMY, B-cell lymphoma, Chronic lymphocytic leukemia, CLL, Bone marrow, Caregiver, Patient, Lymphocytosis, City, CRS, Commercial, Bristol Myers Squibb, BTK, MRD, Cytokine release syndrome, Division, Drug resistance, Multimedia, Blood, Associate professor, Food, Pharmaceutical industry

Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Key Points: 
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
  • Please see the Important Safety Information section below, including Boxed WARNINGS for Breyanzi regarding Cytokine Release Syndrome (CRS), Neurologic Toxicities, and Secondary Hematological Malignancies.
  • “For years, attempts to bring other CAR T cell therapies to patients with relapsed or refractory CLL or SLL met challenges and found little success.
  • After relapsing or becoming refractory to these therapies, patients have few options and poor outcomes, including lack of durable complete responses.

Opentrons Announces New Robotics Education Initiative Demonstrating Commitment to Laboratory Automation for Students

Retrieved on: 
Tuesday, March 12, 2024
University, Biotechnology, Primary, Secondary, Education, Technology, Health, Robotics, Other Science, Research, Science, Hardware, Automation, Virginia Tech, Assistant, Data analysis, MIT, Research design, University College London, Student, Ecosystem, Colorado State University, J. Craig Venter Institute, Carnegie Mellon University, Teaching, Associate professor

Opentrons Labworks, Inc ., a leader in lab automation and makers of accessible lab robotics, today announced the launch of Opentrons® for Education, an exclusive offering for educators to bring lab automation to the classroom.

Key Points: 
  • Opentrons Labworks, Inc ., a leader in lab automation and makers of accessible lab robotics, today announced the launch of Opentrons® for Education, an exclusive offering for educators to bring lab automation to the classroom.
  • Opentrons is building a first-of-its-kind ecosystem for teaching with automation, which includes education pricing and support, along with access to a community of educators already teaching with Opentrons.
  • Opentrons for Education is the key to unlocking a new era of hands-on, innovative learning in the realm of laboratory sciences.
  • in Automated Science Program, Computational Biology Department at Carnegie Mellon University, said, “This initiative underscores Opentrons' commitment to shaping the future of laboratory automation education for aspiring scientists.

Adcendo ApS to Present Data on its Novel ADC Target uPARAP in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Thursday, April 4, 2024
Research, Glioblastoma, Patient, GBM, Tumor microenvironment, University, Spacecraft, Abstract (summary), Biology, Mesothelioma, AACR, PDX, Cancer, University of Copenhagen, Poster, Finsen Laboratory, GIST, ADC, Invasion, Receptor (biochemistry), Associate professor

The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark.

Key Points: 
  • The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark.
  • uPARAP is a novel ADC target overexpressed by mesenchymal cancer cells including soft tissue and bone sarcomas, GIST as well as mesothelioma and glioblastoma, and has the potential to play a key role in modulating the tumor microenvironment.
  • The data demonstrate that uPARAP is strongly over-expressed in glioblastoma cells and that a uPARAP targeting ADC exhibits strong in vivo anti-tumor activity in a glioblastoma PDX model.
  • We are extremely encouraged by the data highlighted in this study, which provides further evidence on the potential effectiveness of uPARAP as a novel target for ADCs in glioblastoma multiforme.

Adcendo ApS to Present Data on its Novel ADC Target uPARAP in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Thursday, April 4, 2024
Research, Glioblastoma, Patient, GBM, Tumor microenvironment, University, Spacecraft, Abstract (summary), Biology, Mesothelioma, AACR, PDX, Cancer, University of Copenhagen, Poster, Finsen Laboratory, GIST, ADC, Invasion, Receptor (biochemistry), Associate professor

The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark.

Key Points: 
  • The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark.
  • uPARAP is a novel ADC target overexpressed by mesenchymal cancer cells including soft tissue and bone sarcomas, GIST as well as mesothelioma and glioblastoma, and has the potential to play a key role in modulating the tumor microenvironment.
  • The data demonstrate that uPARAP is strongly over-expressed in glioblastoma cells and that a uPARAP targeting ADC exhibits strong in vivo anti-tumor activity in a glioblastoma PDX model.
  • We are extremely encouraged by the data highlighted in this study, which provides further evidence on the potential effectiveness of uPARAP as a novel target for ADCs in glioblastoma multiforme.